Citius Pharmaceuticals, Inc. (CTXR) - Form 8-K Summary
Business Context and Reporting Period
Citius Pharmaceuticals, Inc., a Nevada corporation, filed this Current Report on Form 8-K on May 15, 2026. The filing announces the results of operations for the second quarter of fiscal 2026. The company's common stock trades on The Nasdaq Capital Market under the symbol CTXR.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the provided text.
Material Changes
The filing does not disclose specific material changes versus the prior comparable period. It serves solely as a notification that the second quarter fiscal 2026 results have been issued.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies and unusual items. The document explicitly states that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 15, 2026) for actual Q2 2026 financial figures.
- Verify the company's cash runway and burn rate, as these are not stated in the 8-K text.
- Check for any updated clinical trial milestones or regulatory developments mentioned in the full press release.
- Confirm the status of the company's debt obligations and liquidity position from the referenced exhibit.